DUBLIN--(BUSINESS WIRE)--Feb 23, 2021--

The "Biologics Contract Development and Manufacturing Organization (CDMO) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The global biologics CDMO market (henceforth, referred to as the market studied) was valued at USD 9.93 billion in 2020, and it is expected to reach USD 18.90 billion by 2026, registering a CAGR of 11.2% during 2021-2026 (henceforth, referred to as the forecast period).

The global pharmaceutical industry is growing at an exponential rate and is expected to reach USD 1.52 trillion in annual sales by 2023, which is driven by global economic growth, a growing and aging population, and new product launches. Even though small molecules continue to command the prominent share of the market, large molecules, such as biologics, biosimilars, and cell and gene therapies, are expected to witness the fastest growth over the forecast period.

Even though volumes in large molecules tend to be smaller, the segment is growing at a faster pace. Absolute growth in the large molecules market, including both originator biologics, biosimilars, and cell and gene therapies, is projected at USD 133 billion by 2023. The market size for originator biologics is expected to reach USD 371 billion by 2023, according to Results Healthcare.

Cancer therapies are among the primary drivers for a large proportion of the growth in the biologics market. Even with the faster growth forecast, in terms of drug approvals, small molecules outweigh biologics. For instance, in 2018, the FDA approved 42 new small molecule products, whereas biologics approval amounted to just 17. However, the number of biologic approvals has been increasing steadily over the past few years.

The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic. This pandemic has impacted multiple aspects of the biopharma industry, from drug development, clinical trials, supplies, manufacturing, to supply chain logistics. However, the drug shortages due to COVID-19 are limited, and they are expected to remain so for short-term, due to stockpiles of pharmaceuticals, APIs, globally. Among the issues being faced across the supply chains, China and India have been impacted the most due to being the largest global producers of active pharmaceutical ingredients (APIs) and generics.

Chinese manufacturing facilities were significantly reduced. The major extent has been a number of typical workforce who were unable to return to work, which led to underutilized efficiency across multiple levels in the industry. Furthermore, short-term scarcities were announced by the US Food and Drug Administration (FDA) back in February 2020, due to API manufacturing delays.

Major players of the market include Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, and Fujifilm Diosynth Biotechnologies USA Inc among others.

Key Topics Covered:


1.1 Study Assumptions and Market Definition

1.2 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Access to New Technologies and Higher Speed of Execution Realized by CDMOs

4.2.2 Need for High Capital Investments to Develop Capabilities Has Led to Firms Choosing the Outsourcing Model

4.2.3 Lack of In-house Capacity among the Emerging Drug Development Companies

4.3 Market Challenges

4.3.1 Transfer Complexities and Concerns over the Breach of IP and Patents

4.3.2 Capacity Issues Related to Large-molecule Drugs

4.4 Market Opportunities

4.4.1 Emergence of the Concept of Biosimilars Co-development and Designer Cell Lines

4.5 Key Considerations Involved in the Selection of a Biologics CDMO Vendor

4.6 Business Model Analysis - Value Added, Flexible Capacity Risk Sharing, and In-time Manufacturing

4.7 Detailed Assessment of the Impact of COVID-19 on Biologics CDMO (The Race for the Development of a New Vaccine and Impact on the Current Capacities)

4.8 Key Trends in Biopharmaceutical Industry

4.9 Coverage on the Current Use of Biologics for Different Types of Disease Treatment - Oncology, Infectious, Cardiovascular, Etc.


5.1 Type

5.1.1 Mammalian

5.1.2 Non-mammalian (Microbial)

5.2 Product Type

5.2.1 Biologics Monoclonal (Diagnostic, Therapeutic, and Protein-based) Recombinant Proteins Antisense and Molecular Therapy Vaccines Other Biologics

5.2.2 Biosimilars

5.3 Geography


6.1 Company Profiles

6.1.1 Boehringer Ingelheim Group

6.1.2 Wuxi Biologics

6.1.3 Samsung Biologics

6.1.4 Lonza Group

6.1.5 Fujifilm Diosynth Biotechnologies USA Inc.

6.1.6 Toyobo Co. Limited

6.1.7 Parexel International Corporation

6.1.8 PRA Health Sciences

6.1.9 Binex Co. Limited

6.1.10 JRS Pharma

6.1.11 Rentschler Biotechnologies

6.1.12 AGC Biologics

6.1.13 Sandoz Biopharmaceuticals

6.1.14 Catalent Inc.

6.1.15 AbbVie Contract Manufacturing




For more information about this report visit https://www.researchandmarkets.com/r/cyjmm5

View source version on businesswire.com:https://www.businesswire.com/news/home/20210223005613/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 02/23/2021 06:39 AM/DISC: 02/23/2021 06:39 AM


Copyright Business Wire 2021.

Recommended for you

(0) comments

Welcome to the discussion.

Real Names required. No pseudonyms or partial names allowed. Stand behind what you post.
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.